Scholar Rock Holding Corporation (SRRK)
| Market Cap | 1.08B |
| Revenue (ttm) | 15.08M |
| Net Income (ttm) | -97.08M |
| Shares Out | 36.38M |
| EPS (ttm) | -2.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $31.25 |
| Previous Close | $32.43 |
| Change ($) | -1.18 |
| Change (%) | -3.64% |
| Day's Open | 32.12 |
| Day's Range | 30.70 - 33.43 |
| Day's Volume | 257,666 |
| 52-Week Range | 11.33 - 70.00 |
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced a presentation of results from the TOPAZ Phase 2 trial that evaluated apitegromab in patients with Type 2 and Type 3 SMA at EAN
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced an oral presentation of TOPAZ Phase 2 trial results by Dr. Thomas Crawford at the Cure SMA Annual SMA Conference.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces a presentation of apitegromab TOPAZ Phase 2 clinical trial results at the 2021 Virtual SMA Research and Clinical Care Meeting.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock receives fast track designation from the FDA for Apitegromab for the treatment of patients with spinal muscular atrophy.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced a trials in progress poster presentation at the 2021 ASCO Annual Meeting, being held from June 4-8, 2021.
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -10.14% and -29.37%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced that findings from its Phase 1 trial of apitemograb were published in the peer-reviewed journal Advances in Therapy.
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced that the United States Patent Office (USPTO) issued U.S. Patent No. 10,981,981 with an expiry of May 2034.
New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Scholar Rock Holding Corporation ("Scholar Rock" or the "Company") (NASDAQ: SRRK)....
These drugmaker stocks may have been hammered down to bargain-bin prices.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 from April 10 - 15.
Scholar Rock (NASDAQ: SRRK) shares dropped despite the company reporting positive 12-month data on spinal muscular atrophy (SMA) candidate apitegromab. The 12-month update was broadly in line with the s...
Scholar Rock (NASDAQ: SRRK) has announced top-line data from the TOPAZ Phase 2 trial evaluating apitegromab (SRK-015) in patients with Type 2 and Type 3 spinal muscular atrophy (SMA). In Cohort 1 (poole...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced the publication of preclinical development data for SRK-181 in the peer-reviewed journal International Journal of Toxicology.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced issuance of U.S. patent protecting add-on or combination therapy with a myostatin inhibitor for spinal muscular atrophy (SMA).
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announced its oral and poster presentations at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -27.42% and -53.27%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead f...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factor...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factor...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factor...
Investors are fired up about the company's interim phase 2 results for an experimental spinal muscular atrophy drug.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
Scholar Rock Holding Corp. (SRRK) CEO Tony Kingsley on Q2 2020 Results - Earnings Call Transcript
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -22.64% and -40.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for t...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
CAMBRIDGE, Mass--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental...
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -480.00% and -74.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for...
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scholar Rock has been struggling lately, but the selling pressure may be coming to an end soon.
Is (SRRK) Outperforming Other Medical Stocks This Year?
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 31.58% and 38.95%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for...
About SRRK
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor ther... [Read more...]
| Industry Biotechnology | IPO Date May 24, 2018 |
| CEO Nagesh Mahanthappa | Employees 119 |
| Stock Exchange NASDAQ | Ticker Symbol SRRK |
Financial Performance
In 2020, SRRK's revenue was $15.40 million, a decrease of -24.83% compared to the previous year's $20.49 million. Losses were -$86.48 million, 69.6% more than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for SRRK stock is "Buy." The 12-month stock price forecast is 64.67, which is an increase of 106.94% from the latest price.